Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2641–2664 of 84,030 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: therapy Clear all

Conditions: Osteoarthritis Hand, Osteoarthritis Wrist
Interventions: Corticosteroid injection (CSI), Low-dose radiotherapy (LDRT); Drug · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes
Interventions: Targeted Self-Monitoring Of Blood Glucose (SMBG), Provider Training, Patient Education; Other
Lead sponsor: Biomedical Research Institute of New Mexico; Other
Eligibility: 18 Years to 85 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Phoenix, Arizona • Tucson, Arizona • Albuquerque, New Mexico

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Multiple Myeloma
Interventions: Pomalidomide, Carfilzomib, dexamethasone, Daratumumab; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 4
States / cities: Chicago, Illinois • Ann Arbor, Michigan • Detroit, Michigan + 1 more

Conditions: Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia Frontal, Dementia, Mixed, Dementia Alzheimers, Alzheimer Disease, Dementia Severe
Interventions: ADRD-PC Program; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 55 Years and older
Enrollment: 884 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Denver, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 2 more

Conditions: Degenerative Disc Disease
Interventions: Rexlemestrocel-L + HA mixture, Saline; Drug
Lead sponsor: Mesoblast, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 37 more

Conditions: Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer)
Interventions: Bright Light Therapy; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteochondritis Dissecans Knee, Psychological Stress
Interventions: Surgical Treatment, Nonoperative Treatment; Procedure
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 11 Years to 19 Years
Enrollment: 120 participants
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • Frisco, Texas

Conditions: Post-COVID / Long-COVID
Interventions: Placebo, Sipavibart; Drug · Biological
Lead sponsor: Nancy Klimas; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Chronic Pain, Pain
Interventions: Mindfulness-Based Stress Reduction, Cognitive Behavioral Therapy for Chronic Pain, Usual Care; Behavioral · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer, Lung Cancer (Non-Small Cell), Thoracic Cancer, Thymic Cancer, Mesothelioma
Interventions: Complete Cardiac Magnetic Resonance Imaging (MRI); Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cancer Survivorship, Obesity, Overweight
Interventions: Group-based education and discussion, Individual 1:1 counseling, Group based behavioral skills development and cooking demonstrations, BfitBwell; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Obesity
Interventions: Diet + Resistance Training, Diet + Aerobic Training, Diet + Resistance/Aerobic Exercise; Behavioral
Lead sponsor: Biomedical Research Institute of New Mexico; Other
Eligibility: 65 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 2
States / cities: Albuquerque, New Mexico • Houston, Texas

Conditions: Healthy Participants
Interventions: Lorcaserin manufactured at Zofingen, Lorcaserin manufactured at Kawashima; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Metastatic Cancer
Interventions: temozolomide, vinorelbine tartrate; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Time Restricted Feeding
Interventions: Time restricted feeding; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Interventions: E7050, Cetuximab; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 7
States / cities: Tucson, Arizona • Fort Myers, Florida • Boston, Massachusetts + 4 more

Conditions: Asthma
Interventions: Lebrikizumab, Placebo, Inhaled corticposteroids (ICS), Second Asthma Controller Medication; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 12 more

Conditions: Rett Syndrome
Interventions: fenfluramine hydrochloride, Placebo; Drug · Other
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 5 Years to 35 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 8
States / cities: Little Rock, Arkansas • Miami, Florida • Orlando, Florida + 5 more

Conditions: Macular Edema, Cystoid Macular Edema, Uveal Melanoma, Radiation Maculopathy, Radiation Retinopathy
Interventions: Ozurdex, Bevacizumab; Drug
Lead sponsor: Arman Mashayekhi; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced Solid Tumor
Interventions: DB-1310, Trastuzumab, Osimertinib, capecitabine; Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 15
States / cities: Sacramento, California • Santa Monica, California • Coral Gables, Florida + 12 more

Conditions: Prostatic Hyperplasia
Interventions: Treatment sequence A, Treatment sequence B, Treatment sequence C, Treatment sequence D; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Evansville, Indiana • Austin, Texas

Conditions: Catheterization, Peripheral
Interventions: ultrasound, standard technique for venipuncture; Device
Lead sponsor: University of California, Davis; Other
Eligibility: Up to 7 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Mild Cognitive Impairment (MCI), Alzheimer Disease (AD)
Interventions: Education; Behavioral
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 60 Years to 80 Years
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

Radiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis

Impact of Accu-Chek 360 in Veterans With Type 2 Diabetes

A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Palliative Care for Persons With Late-stage Alzheimer's and Related Dementias and Their Caregivers

Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain

Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade

Psychological Response and Readiness Associated With OCD of the Knee

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

An Evaluation of MBSR and CBT for Veterans With Chronic Pain

Cardiac MRI Biomarker Testing (GCC 1618)

BfedBwell Proof-of-Concept Pilot

Lifestyle Intervention Trial in Obese Elderly

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases

Time Restricted Eating Pilot - Bariatrics

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State

Ultrasound Assisted Peripheral Venous Access in Young Children

Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers